The significance of HER-2 amplification and the size and type of pathological unicentric, initially operable clinical stage I and IIA/IIB breast cancer, in determining the treatment strategy

Journal of B.U.ON.

Volumn 17, Issue 1, 2012, Pages 33-37

  Miletic, Nebojsa ^a   Golubicic, I ^b   Gavrilovic, D ^a   Dzodic, R ^b   Pavlovic, T ^a   Nikitovic, M ^b   Stojiljkovic, D ^a   Karaferic, A ^a   Pupic, G ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Breast; Carcinoma; Ductal; HER 2; Lobular; Size

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2;

EID: 84859861024     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Parkin DM. Global Cancer Statistics in the year 2000. Lancet Oncol 2001; 2: 533-543. (Pubitemid 33586866)
2. Lialiaris TS, Georgiou G, Sivridis E et al. Prognostic and predictive factors of invasive ductal breast carcinomas. J BUON 2010; 15: 79-88.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177-182. (Pubitemid 17231334)
4. Menard S, Balsari A, Tagliabue E et al. On behalf of the OMERO group. Biology, prognosis and response to therapy of the breast carcinomas according to HER2 score. Ann Oncol 2008; 19: 1706-1712.
5. Kocic B, Filipovic S, Petrovic B, Mijalkovic D, Rancic N, Poultsidi A. Clinical and biological characteristics of breast cancer. J BUON 2010; 15: 660-667.
6. El Saghir NS, Seoud M, Khalil MK et al. Effects of young age at presentation on survival in breast cancer. Bio Med Central Cancer 2006; 6: 194. DOI: 10.1186/1471-2407-6-194.
7. Goldhirsch A. Glick JH, Gelber RD et al. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 2005; 16: 1569-1583.
8. Hill TD, Khanis HJ, Tyczynski JE, Berkel HJ. Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol 2005; 15/10: 773-780. (Pubitemid 41550245)
9. Aksu G, Duman C, Gurbuz Y et al. Correlation between c-erbB2 expression, lymphovascular invasion and other biological and clinical prognostic factors and preoperative tumor markers in patients with early-stage and locally advanced breast cancer. J BUON 2011; 16: 52-57.
10. Achim W, Christian K, Verena G et al. Effects of guideline adherence in primary breast cancer- A 5- year multi-center cohort study of 3976 patients. The Breast 2010; 19: 120-127.
11. Hamaker ME, Schreurs WH, Uppelschoten JM, Smorenburg CH. Breast cancer in the elderly: retrospective study on diagnosis and treatment according to national guidelines. Breast J 2009; 15: 26-33.
12. Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011; 305: 569-575.
13. Mamounas E, Brown A, Anderson S et al. Sentinel node biopsy after neoadjuvant chemotherapyin breast cancer: results from National Surgical Adjuvant Breast and Bowel project protocol B-27. J Clin Oncol 2005; 23: 2694-2702. (Pubitemid 46179459)
14. Olsha O, Shemesh D, Carmon M et al. Resection Margins in Ultrasound-Guided Breast-Conserving Surgery. Ann Surg Oncol 2011; 18: 447-452.
15. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification. Am J Pathol 2005; 123: 237-243. (Pubitemid 40194085)
16. Di Palma S, Collins N, Bilous M et al. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridization for HER2 analysis in breast cancer. J Clin Pathol 2008; 61: 757-760. (Pubitemid 351859970)
17. Park S, Jiang Z, Mortenson ED et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-170.
18. Dirier A, Burhanedtin-Zincircioglu S, Karadayi B, Isikdogan A, Aksu R. Characteristics and prognosis of breast cancer in younger women. J BUON 2009; 14: 619-623.
19. Baselga J, Bradbury I, Eidtmann H et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. 33rd Annual San Antonio Breast Cancer Symposium, 2010 (abstr S3-3).
20. Finek J, Holubec L Jr, Topolacan O, Elgrova L, Skalova A, Pecen L. The importance of prognostic factors in premenopausal women with breast cancer. Anticancer Res 2007; 27: 1893-1896. (Pubitemid 46954693)
21. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J 2008; 14: 456-463.
22. Smith IE, Lipton L. Preoperative neoadjuvant medical therapy for early breast cancer. Lancet Oncol 2001; 2: 561-570. (Pubitemid 33586869)
23. Dinh P, Sotiriou C, Piccart MJ. The evolution of treatment strategies: aiming at the target. The Breast 2007; 16: 10-16. (Pubitemid 350028549)
24. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684. (Pubitemid 41464706)
25. Haagensen CD, Stout AP. Carcinoma of the breast: Criteria of operability. Ann Surg 1943; 118: 859-870.
26. Veronesi U, Salvadori B, Luini A et al. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomized trials on 1973 patients. Eur J Cancer 1995; 31: 1574-1579.
27. Waljee JF, Hu ES, Ubel PA et al. Effect of esthetic outcome after breast conserving surgery on psycho social functioning and quality of life. J Clin Oncol 2008; 26: 3331-3337.
28. Hossami N, Hayes D. Review of pre-operative magnetic resonance imaging (MRT) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer? CA Cancer J Clin 2009; 59: 290-302.